[go: up one dir, main page]

MX2023009962A - Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. - Google Patents

Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.

Info

Publication number
MX2023009962A
MX2023009962A MX2023009962A MX2023009962A MX2023009962A MX 2023009962 A MX2023009962 A MX 2023009962A MX 2023009962 A MX2023009962 A MX 2023009962A MX 2023009962 A MX2023009962 A MX 2023009962A MX 2023009962 A MX2023009962 A MX 2023009962A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
combined pharmaceutical
inhibitor
composition containing
present disclosure
Prior art date
Application number
MX2023009962A
Other languages
English (en)
Inventor
Xiquan Zhang
Xunqiang Wang
Ding Yu
Fan Feng
Yanfeng Bai
Chaoqiang Yang
Yuying Zhang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023009962A publication Critical patent/MX2023009962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente descripción se refiere a una composición farmacéutica combinada que contiene un inhibidor de CDK4/6 y su uso, y específicamente se refiere a una composición farmacéutica combinada que comprende un compuesto de fórmula (I) o la sal farmacéuticamente aceptable de este y fulvestrant. La presente descripción se refiere además al uso de la composición farmacéutica combinada en el tratamiento del cáncer de mama. La composición farmacéutica combinada de la presente divulgación produce mejores efectos terapéuticos en la reducción del crecimiento tumoral o incluso en la eliminación de tumores. (ver Fórmula).
MX2023009962A 2021-03-03 2022-03-03 Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. MX2023009962A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110236331 2021-03-03
PCT/CN2022/079100 WO2022184146A1 (zh) 2021-03-03 2022-03-03 Cdk4/6抑制剂的联用药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2023009962A true MX2023009962A (es) 2023-09-05

Family

ID=83154727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009962A MX2023009962A (es) 2021-03-03 2022-03-03 Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.

Country Status (8)

Country Link
US (1) US20240139208A1 (es)
EP (1) EP4302763A4 (es)
CN (2) CN116940363A (es)
AU (1) AU2022231254A1 (es)
BR (1) BR112023017116A2 (es)
CA (1) CA3208807A1 (es)
MX (1) MX2023009962A (es)
WO (1) WO2022184146A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165068A1 (zh) * 2023-02-09 2024-08-15 正大天晴药业集团股份有限公司 取代2-氢-吡唑衍生物的联用药物组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809312A1 (en) * 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
LT3033086T (lt) * 2013-08-14 2021-12-27 Novartis Ag Kombinuota terapija vėžiui gydyti
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
WO2016012982A1 (en) * 2014-07-25 2016-01-28 Piramal Enterprises Limited Combination therapy for the treatment of resistant breast cancer
JP6726677B2 (ja) 2015-03-11 2020-07-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. 抗がん剤としての置換２−ｈ−ピラゾール誘導体
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
JP7100625B2 (ja) * 2016-09-09 2022-07-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 置換２－ｈ－ピラゾール誘導体の結晶形、塩型及びその製造方法

Also Published As

Publication number Publication date
US20240139208A1 (en) 2024-05-02
AU2022231254A1 (en) 2023-09-28
CN120022281A (zh) 2025-05-23
WO2022184146A1 (zh) 2022-09-09
CA3208807A1 (en) 2022-09-09
BR112023017116A2 (pt) 2023-09-26
CN116940363A (zh) 2023-10-24
EP4302763A4 (en) 2024-11-27
EP4302763A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0312464A (pt) Inibidores de tirosina quinases
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA201201159A1 (ru) Дейтерированные соединения пирролопиримидина в качестве ингибиторов cdk4/6
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024002409A (es) Terapias contra el cancer.
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
DOP2025000046A (es) Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
MX2023009166A (es) Derivados de quinoxalina y sus usos.
MX2021009188A (es) Uso de composición que contiene inhibidor de quinasa dependiente de ciclina 4/6 en combinación con anastrozol en la preparación de medicamentos para el tratamiento de enfermedades tumorales.
MX2010010561A (es) Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos.